Ten patients with acute leukemia after primary myelodysplastic syndrome (MDS-AL) were examined to clarify the biologic nature of the leukemic cells in comparison with that of de novoacute myelocytic leukemia (AML). The morphologic and cytochemical features of the leukemic cells from all these patients corresponded well to those of de novo AML, and they were diagnosed with MDS-AML. Phenotypically, the frequent expression of the lymphocyte activation antigens, CD25 and CD30, was characteristic in MDS 
In this study, we examined leukemic cells from 10 patients with MDS-AML to clarify their biologic nature. Leukemic cells from all of the patients had marked myeloid features, and were diagnosed as MDS-AML. There was no significant difference of lineage-associated phenotype between MDS-AML and de novo AML, although the expression of the lymphocyte activation antigens, CD25 and CD30, was frequent in MDS-AML. The MDS-AML cells from all patients responded to one or more growth factors, but TGFPl did not inhibit the factor-dependent growth of MDS-AML cells, in contrast to its action in bone marrow cells from normal volunteers, MDS patients, and de novo AML patients.
MATERIALS AND METHODS
Patients. Eleven patients with MDS-AL, 20 patients with de novo AML, and 4 patients with MDS were examined in this study. In addition, 2 15 patients with de novo AML, including the 20 de novo AML patients above, were examined for an immunophenotypic study. All patients gave their informed consent for the procedure involved. Diagnosis of MDS and AML was made on the basis of the French-American-British (FAB) clas~ification.'~~'~ All of the MDS-AL patients had been in the MDS clinical phase for more than 6 months preceding the acute leukemic phase.
Heparinized peripheral blood cells or bone marrow aspirates, obtained from these patients with their informed consent, were used for the preparation of mononuclear cells (MNC) by Ficoll-Hypaque density gradient centrifugation (d = 1.077). Tcell-and adherent-cell-depleted MNC were used as leukemic-cellenriched MNC. Stored samples, frozen at -196°C in RPMl1640 medium with 20% heat-inactivated fetal calf serum (FCS; GIBCO Labs, Chargrin Falls, OH) and 10% dimethylsulfoxide (DMSO), were used as needed. The AML cell lines, HL-60 and Kasumi-I, were also used. The Kasumi-1 cell line" was kindly provided by Dr N. Kamada (Hiroshima University, Hiroshima, Japan).
Surface marker analysis was performed by indirect immunofluorescence with a panel of antibodies (Ab). Before immunostaining, all samples were treated with 5% heat-inactivated human AB serum for blocking the binding of monoclonal Ab (MoAb) with receptor for the IgC Fc portion (FcrR). CDI Ib(detected by OKMI), CD13 (by MCSZ), CD14 (by My4), CD15 (by LeuMI), CD33 (by My9), CD34 (by MylO), and CD41 (by J 15) were tested as myeloid markers; CD2 (by TI I), CD3 (by Leu4), CD4 (by Leu3a), CD5 (by LeuI), CD7 (by Tp40), and CD8 (by Leu2) were tested as T-cell markers; and surface Ig (sIg), CD19 (by Leu12), and CD20 (by Leul6) were tested as B-cell
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Samples were evaluated by flow cytometry (Cytoron; Ortho Diagnostic Systems, Tokyo, Japan), light microscopy, or immunofluorescence microscopy (Olympus, Tokyo, Japan). At least 5,000 cells were examined for the surface marker study, and 200 cells were examined for the CD30 and TdT studies. Samples were considered heavy chain (IgH), T-cell receptor fl chain (TCRP), and TCRy genes were JH for the IgH joining (J) region genes, CPl for the TCRP constant (C) region genes, J y l for the TCRy J y l region genes, and Jb2 for the TCRb J region genes. The DNA probes for Ig and TCRP genes were kindly provided by Dr T. Honjo (Kyoto University), the DNA probe for TCRy was provided by Dr T.H. Rabitts (Cambridge University, Cambridge, UK), and the probe for TCRb was provided by Dr Y . Takihara (Osaka University, Osaka Japan).
Clonogenic assay with various cytokines. Leukemic colony assay was performed in methylcellulose semisolid culture." Leukemic cells were suspended in Iscove's modified Dulbecco's medium (IMDM) supplemented with 40% heat-inactivated FCS and adjusted to a concentration of 2 X IO5 cells/mL. Fifty microliters of the cell suspension and an equal volume of IMDM supplemented with an optimal dose of single or combined growth factors, 2% methylcellulose (Nakarai Chem Co, Kyoto, Japan), and 2% deionized bovine serum albumin (BSA; Armour Pharmaceutical Co, Kankakee, IL) were gently mixed. These suspended cells were cultured in a 96-microwell culture plate (flat bottom; Costar, Cambridge, MA) at 37°C in a fully humidified incubator with 5% CO, for 7 days. Cell culture without factor@) served as a control. The number of colonies (>20 cells) was counted under an inverted microscope (Olympus). All the cultures were performed in triplicate, and the results are shown as the mean number with standard deviation (SD).
The stimulating factors used were recombinant human IL-3 (rhIL-3; IO ng/mL), granulocyte-macrophage colony-stimulating factor (rhGM-CSF; 10 ng/mL), granulocyte-CSF (rhG-CSF IO ng/ mL), and TGFPl ( 1 or 4 ng/mL). G-CSF was kindly provided by Chugai Pharmaceutical Co (Tokyo, Japan). IL-3 and GM-CSF were purchased from Genzyme Inc (Boston, MA). TGFP1, purified from human platelets, was purchased from R&D System Co (Minneapolis, MN). The purity of CSF (or cytokine) in each recombinant product was more than 95%.
A binding assay was performed using "'I-recombinant human TGFP 1, as described p r e v i o~s l y .~~ Briefly, leukemic cells, adjusted to an appropriate concentration (between I and 3 X IO6 cells), were incubated for I hour at 23°C in 100 p L of DMEM (supplemented with 0.1% BSA and 25 mmol/L HEPES, pH 7.4) and increasing concentrations of '"I-TGFPl, with or without an excess of the unlabeled factor. Incubation mixtures, trans-
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For ferred to 400 pL polyethylene tubes containing 200 pL of oil mixture (80% di-n-butylphtalate and 20% olive oil), were centrifuged for 2 minutes at 7,000 rpm. The cell pellets were removed by cutting the tubes with a razor blade, and cell-mediated radioactivity was determined in a y-counter. Free radioactivity in the supernatants was also determined. mic cells in comparison to that of 2 15 de novo AML samples. There were no differences in CD 13, CD33, CD34, or HLA-DR positivities between MDS-AML and de novo AML, whereas the positivities of CD I lb, CD34, and ~~2 5 in MDS-AML were higher than those in de novo AML (Table l). CD7 was also detected in 5 samples. The contaminated normal T cells were assessed by considering the expression of CD3. In fact, contaminated T cells constituted less than 5% of the whole mononuclear fraction from each sample. In addition, CD30, which was expressed in leukemic cells from 4 patients, was detected only in the cytoplasm in 3 of the samples. Both TCR and IgH genes in all 9 MDS-AML samples examined were in germline configurations. Various karyotypic abnormalities were found in 6 of the 1 1 MDS-AML patients, but no cOmmOn abnomal karyotype was detected (data not shown).
Response of MDS-AML and de novo AML cells to growth
tients formed spontaneous colonies without any growth factors in in vitro culture (Fig 1) . IL-3, GM-CSF, and G-CSF 
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Effects of TGFDl on MDS-AML cells.
For In MDS-AML, leukemic colony formation in 3 of 5 samples shnwino snnntanpniir ornwth in 8 nf 10 I1 -7 resnnnrlers in 1---.. ---~ 1 r -_-.------I o-- .. ---, --_ v -----I I ---=-------, ---7 of 9 GM-CSF responders, and in all of 4 G-CSF responders was not inhibited by 4 ng/mL of TGFP1. The percent inhibition of cytokine-dependent leukemic colony formation by both 1 and 4 ng/mL of TGFP 1 was not significant compared with control colony formation (Fig 2A) . In addition, more than IO ng/mL of TGFPl did not affect the growth factor-dependent growth of MDS-AML cells from all of 3 samples examined (data not shown).
On the other hand, in de novo AML, TGFPl inhibited leukemic colony formation in 8 of 9 samples showing spontaneous growth, in 13 of 14 IL-3 responders, in 16 of 17 GM-CSF responders, and in 10 of 11 G-CSF responders. TGFPl-resistant growth was observed in the same sample. Inhibition by TGFPl occurred in a dose-dependent manner in all samples (Fig 2B) . TGFPl inhibited IL-3-and GM-CSF-dependent growth of bone marrow cells from 4 MDS patients but not G-CSF-dependent growth similar to normal bone marrow cells (Fig 2C) .I3 The difference between MDS-AML cells and de novo AML cells in the growth inhibition by TGFBl was significant ( Table 2 ). TGFPl did not inhibit any growth factor-dependent growth of HL-60 cells, but significantly inhibited the IL-3-, GM-CSF-, and G-CSF-dependent growth of Kasumi-1 cells.
Specific binding to '251-labeled TGFPl was found in both MDS-AML cells and de novo AML cells (Table 3 and Fig 3) . Scatchard analysis of the binding showed two types of binding sites with different dissociation constants (kd): high-affinity and low-affinity binding sites. The number of high-affinity binding sites on MDS-AML cells was less than that on de novo AML cells. Leukemic cells from 3 de novo AML samples (samples 1, 2, and 5 in Table 3 ) did not express low-affinity binding sites; however, their growth factor-dependent growth was definitely inhibited by TGFP 1. HL-60 cells had 43 high-affinity and 195 low-affinity binding sites, and Kasumi-1 had 220 high-affinity and 1,478 low-affinity binding sites. All MDS-AML and de novo AML samples examined consisted of more than 80% of blastic cells morphologically and phenotypically, indicating that the number of binding sites could be regarded to be representative.
DISCUSS ION
We describe here the biologic characteristics of MDS-AML cells. Recently, San Miguel et all7 described a high incidence of MDS-AL cells showing lymphoid nature. The nature of the leukemic cells from our patients, however, corresponded to that of de novo AML cells, especially to that of acute monocytic leukemia. CD7 expression in 4 patients is considered not to be an indicator of lymphoid nature but to be due to immaturity; this hypothesis would also cover the lack of other T-cell antigens, the rearranged TCR genes, and the expression of CD34 and HLA-DR.2"26 CD25 and CD30 were frequently expressed on MDS-AML cells. Hematopoietic neoplasms expressing CD25 and/or CD30 are well known to have unique characterist i c~.~~,~~ CD25 expression in such neoplasms is excessive but not f~n c t i o n a l .~~,~~ Because these antigens are expressed on activated normal hematopoietic cell^,*^^^^ this phenomenon may indicate that MDS-AML cells are in an activated state. CD25 is IL-2Ra" and CD30 is recognized as a member of the nerve growth factor s~p e r f a m i l y .~~ As mentioned below, the number of TGFPl receptors on MDS-AML cells reduced. TGFPl is thought to regulate the expression of growth factor receptors33; thus, it is possible that CD25 and CD30 expression in MDS-AML cells may be related to the reduced numbers of TGFP 1 receptor.
MDS-AML cells responded well to growth factors in vitro
Expression of TGFP receptor on MDS-AML cells.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From to the same extent as de novo AML cells. However, in contrast to its action on de novo AML cells, TGFPl exerted little influence on the growth factor-dependent proliferation of AML-MDS cells. TGFP is recognized as an important negative regulatory factor of both normal and neoplastic hematopoietic progenitor cell^.'^.'^ Thus, these findings suggest that MDS-AML cells are free from the regulation by TGFP 1.
Keller et a134 reported that leukemic cell lines that did not respond to TGFPl lacked TGFP 1 receptors. The number of high-affinity binding sites on MDS-AML cells was lower than that on de novo AML cells. Here, because the number of high-affinity TGFPl binding sites reduced but was still expressed on cells from most of MDS-AML, a question as to whether such a degree of the reduction is biologically different was raised. However, all of the MDS-AML samples lost cellular response to TGFP 1, and HL-60, which did not respond to this factor, had 43 affinity binding sites of TGFP I. These findings suggest that the loss of growth-inhibitory response to TGFPl is related to reduced numbers of TGFPl receptors on the cells. We also cannot rule out this possibility due to abnormalities in the signal transduction system of the TGFP receptor.
Four different binding components of TGFP receptors have been identified, and TGF receptor type I and type I1 are thought to act as high-affinity TGFP 1 receptors on hematopoietic ~e l l s .~~"~ However, the biologic significance of low-affinity TGFP 1 binding sites on hematopoietic cells is unclear. Because de novo AML cells without the low-affinity binding sites responded well to TGFPl, it would appear that this type of binding site exerts little effect on leukemic cell growth.
Our results suggest that the reduced TGFPl receptor may represent disregulation of the proliferation system in MDS-AML cells. This event seems to occur during the MDS phase, as indicated by the finding that the growth factor-dependent proliferation of bone marrow cells in MDS was strongly inhibited by TGFPl. It is probable that this phenomenon is somehow related to the poorer prognosis of patients with MDS-AML.
